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Case presentations
Patient 1. A 49-year-old woman was transferred to University of
Colorado Hospital for treatment of hyponatremia and an altered mental
status. For 2 days prior to admission to a local hospital, she had
complained of increasing malaise, weakness, and "feeling drunk." Her
behavior became increasingly inappropriate and, on the evening of
admission, her family had difficulty arousing her and took her to a local
emergency room. Her medications included ciorazepate, hydrochlo-
rothiazide, atenolol, nortriptyiine, and amitriptyline. She had a history
of hypertension, chronic anxiety, alcohol abuse, and she had been
hospitalized in 1987 for hyponatremia.
On physical examination in the emergency room, the patient was
uncomfortable and inattentive but was oriented to person and able to
answer brief questions. The blood pressure was 150/70 mm Hg; pulse
rate, 84 beats/mm; and respiratory rate, 20/mm. Cranial nerves were
intact but her speech was mildly slurred. Her sensory and motor
functions and reflexes were normal but she had bilaterally up-going
toes.
Laboratory examination revealed: sodium, 98 mEq/liter; potassium,
1.6 mEq/liter; bicarbonate, 21 mM/liter; chloride, 59 mEq/liter; glucose,
154 mg/dl; BUN, 5 mg/dl; uric acid, 1.8 mg/dl; T4, 17.7 g/dl; hemato-
crit, 41%; urine sodium, 38 mEq/liter; urine potassium, 41 mEq/liter;
and urine osmolality, 248 mOsm/kg H20. A trace of acetaminophen and
therapeutic levels of amitriptyline and nortriptyline were detected on
toxicology screen; ethanol was not present.
The patient initially was treated with 0.9% saline at 250—500 mi/hr.
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Three hours later, she was awake and slightly lethargic; the serum
sodium had risen to 104 mEq/liter. Although the attending physician
was surprised at how well she appeared given her electrolyte abnor-
mality, 3% sodium chloride was added to the regimen at a rate of 300
mI/hr. As Figure 1 illustrates, the serum sodium had risen to 120
mEq/liter within 12 hours of admission and rose slowly thereafter to 131
mEq/liter over the next 12 hours. Although restless, she was alert and
oriented and was described as "neurologically intact." Fluid restriction
was ordered. The next morning, her serum sodium was 134 mEq/liter
but she was uncommunicative and became less responsive. A CT scan
of the head was normal.
Because of continued neurologic deterioration, she was transferred to
University Hospital and required intubation en route. On arrival, her
blood pressure was 170/72 mm Hg; pulse rate, 124/mm; and tempera-
ture, 38.3° C rectally. Over the next 24 hours, she became even less
responsive and developed disconjugate eye movements, decreased
muscle strength, and decreased reflexes. The progressive development
of quadriparesis promoted the clinical diagnosis of central pontine
myelinolysis (CPM). A magnetic resonance imaging scan performed at
this time was normal (Fig. 2, top). The study was repeated 8 days later,
however, and it revealed hyperdense lesions both in the pons (Fig. 2,
bottom) and in extrapontine areas, consistent with central pontine
myelinolysis. Her clinical status contined to deteriorate, and she died 45
days after transfer.
Patient 2. A 31-year-old woman was admitted to another hospital for
a hysterectomy. The medical history was unremarkable except for
irregular uterine bleeding and a tubal ligation 2.5 years prior to
admission. After surgery she received demerol and levodromoran for
relief of pain and thorazine for relief of nausea. The next morning, the
patient was found to be vomiting and did not respond to commands.
The serum sodium concentration (reported 2 hours later) was 114
mEq/liter and the serum potassium was 2.4 mEq/liter. Thorazine was
administered; 2 hours later, she had a respiratory arrest and was
intubated. Her pupils became fixed and dilated, and she was areflexic.
A spinal tap revealed xanthochromic fluid. The next day a CT scan
showed cerebral edema, and an electroencephalogram revealed no
electrical activity. She died 9 days later. Review of the hospital records
revealed that she had received 4.5 liters of D5W prior to the respiratory
arrest. Urine output was approximately 950 cc between the time of
surgery and the arrest.
Discussion
DR. TOMAS BERL (Professor of Medicine, University of
Colorado School of Medicine, Denver, Colorado): These two
patients illustrate quite dramatically the catastrophic neurologic
consequences associated with hyponatremia. Whereas one of
them (Patient 1) developed the neurologic syndrome following
vigorous treatment of her electrolyte abnormality, the other
(Patient 2) did so in the Thsence of any therapeutic intervention
directed at correcting the hyponatremia. These patients poi-
gnantly reflect the difficult therapeutic dilemma facing the
physician who encounters a symptomatically hyponatremic
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patient: how promptly and rapidly should the electrolyte disor-
der be corrected? An attempt to find an answer to this dilemma
in the medical literature may well leave the reader perplexed.
Some authorities strongly defend the view that symptomatic
hyponatremia requires prompt treatment, noting that a "laissez
faire" approach can culminate in severe irreversible neurologic
impairment and even death [1—5]. On the other hand, others
have noted the development both of pontine and extrapontine
demyelinating lesions in patients whose hyponatremia had been
treated [6—10]. These authors wonder whether the treatment of
hyponatremia is "unsafe at any speed" [6]. In caring for the
hyponatremic patient, therefore, we seem caught in the unen-
viable vise of being "damned if we do [treat] and damned if we
don't." Is there a way out of this predicament? I believe there
is. I believe experimental studies of the cerebral response to
hypotonicity and its correction as well as the clinical experience
accumulated by various investigators over the years can be
used to develop general guidelines to a rational and safe
approach to the therapy of hyponatremia. I will review the
available evidence with this goal in mind.
Consequences of untreated hyponatremia
The events accompanying the excessive administration of
water in various mammals were first described by Rowntree
more than 60 years ago [11]. He recognized that the brain
carries the primary pathologic burden of the electrolyte disor-
der accompanying overhydration. Noting that animals given
excess water developed cerebral edema, Rowntree recorded
high intracranial pressure, and he observed improvement after
decompression of the skull. In 1935 Helwig and colleagues
described the first fatal case of water intoxication in a 50-
year-old woman who received 9000 ml of water following a
cholecystectomy [12]. The brain was uniformly enlarged, the
ventricles reduced in size, the cerebral gyri flattened, and the
subarachnoid space obliterated; swelling of glial structures was
seen on microscopic examination. Since this original descrip-
tion, few pathologic studies have been reported in patients who
died shortly after the onset of acute hyponatremia. Cerebral
edema was reported in 3 psychiatric patients with water intox-
130 ication [13—15], one of whom had uncal and tonsillar herniation
[13]. Likewise, in Arieff's recent series of women with hypona-
tremia after elective surgery, all 3 patients who were studied at
autopsy had brain stem herniation [2]. Nevertheless, the dra-
matic neuropathology that accompanies the development of
1110 acute hyponatremia clearly is encountered much less frequently
3 than would be expected if osmotic equilibration were achieved
100 solely by water movement into the brain. The adaptive processthat serves to mitigate cerebral cellular swelling is important in
determining the development of symptoms in these patients and
90 probably is critical in predisposing to complications related to
treatment.
Cerebral adaptation. Numerous studies in experimental ani-
mals have demonstrated that the brain is relatively resistant to
osmotic swelling [16—20]. The water increment in brain content
in the first 6 hours after water loading [19] is only approximately
40% of that predicted on the basis of ideal osmotic behavior, a
discrepancy that becomes even more marked with time [21].
Given that brain tissue and plasma remain in osmotic equilib-
rium [18, 22], this discrepancy requires that homeostatic pro-
cesses be activated promptly after the onset of hypoosmolality.
The first line of defense appears to be an increment in the flow
of fluid from the interstitial space of the brain into cerebral
spinal fluid (CSF) [23, 24], a process that is reversed in
hypertonic states [25]. As Figure 3 shows, water entering the
brain in the initial response to hypotonicity can increase hydro-
static pressure in the interstitial space, thereby providing a
pressure gradient for fluid movement into the CSF via extracel-
lular channels [26]. The excess CSF then enters the systemic
circulation. The presence of this adaptive response is supported
by the observation that in the first 3 hours of dilutional
hyponatremia, the intracellular volume increases as predicted
from the decrement in osmolality, while extracellular volume
actually falls below predicated values [23]. The importance of
increased interstitial pressure is also underlined by the obser-
vation that this pattern of adaptation is not seen in newborn
puppies in which a compliant cranium allows for more cerebral
swelling [27]. The acute decrement in the sodium and chloride
content of brain, a decrease that accompanies this process, is
likewise abrogated.
The second, somewhat slower, defense mechanism that
becomes operative within hours of the onset of hyponatremia is
the loss of cell solutes, primarily potassium [19, 28, 29].
Whereas a decrement in brain sodium and chloride content can
be measured within 30 minutes, a decrement in brain potassium
is measurable only at 3 hours after the onset of hyponatremia
[19]. More prolonged hyponatremia is associated with almost
complete normalization of brain water content [21, 28, 30, 31].
Whether measured after 74 hours [281 or 21 days of hypona-
tremia [31], however, the decrease in measured monovalent
electrolytes is clearly much less than that required to account
for the observed degree of cell volume regulation. In fact, in the
various studies in which it has been measured, the loss of
electrolytes is remarkably similar and limited to 15% to 20%.
Therefore other osmolytes, most likely organic in nature,
appear to be involved in the process. Although the total brain
amino acid content is decreased in hyponatremic mice (by
approximately 50%) [32], the decrement is most striking for the
amino acid taurine (approximately 70%). In fact, on a molar
basis, the contribution of amino acid loss is greater than that of
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Fig. 1. Increase in serum sodium after admission and rate of increase
in serum sodium at each hour in Patient 1. Note that the patient's serum
sodium rose by 36 mEq/liter within 12 hours.
Time after admission, hours
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Fig. 2. Magnetic resonance imaging of the brain 2 days (top) and 10 days (bottom) after hospitalization in Patient 1. Demyelinating lesions seen
at the bottom are absent in the initial examination.
Duration of hyponatremia
Acute hypotonicity
Group I Group II Group Ill
- (7 hours) (26 hours) (74 hours)
I I I I I I
110% -
Increased cerebral swelling
100% — /V/I / /
Increased interstital hydrostatic pressure 0 90% -
80% /Increased flow of fluid to CSF /
70%
Systemic circulation Fig. 4. Brain water (solid bars), NA, and K contentswere measured 2
hours after an intraperitoneal injection of 0.1 saline to animals that had
been hyponatremic for 7 hours (Group 1), 26 hours (Group II), or 74
Fig. 3. Mechanisms of increased CSF flow in hyponatremia. hours (Group III). It is assumed that this injection did not alter the
plasma Na concentration and merely prolonged the disturbance for an
additional 2 hours. Total brain solute (hatched bars) was calculated
potassium, as depicted in Figure 4. The loss of these organic from the measured increase in brain water and the measured decrease
osmolytes is a delayed response, correlated in time with the in plasma Na concentration. Open bars depict brain cation content.
normalization of brain water. This adaptation may be of partic- (From Ref. 28.)
ular importance in severe hypotonic states if the loss of elec-
trolytes is limited to approximately 20%. In view of the clinical osmolytes is also of greater importance in states in which the
observations that I will discuss in a moment, it would be of loss of cellular electrolytes can be more limited, as in potassium
great interest to study whether the contribution of organic depletion.
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Morbidity and mortality. The underlying cause, the severity,
and the rate of development are widely recognized as the
primary determinants of the clinical manifestations of hypona-
tremia. Signs or symptoms of hyponatremia are unusual unless
the sodium has fallen below 125 mEq/liter and has reached this
level in less than 24 hours [3, 33]. Nausea, emesis, and
headaches are seen most consistently; seizures, respiratory
arrest, and stage-IV coma occur in a high percentage of patients
[2, 12—14, 34—54]. Nonetheless even in a report that attempted
to deemphasize the complications of untreated hyponatremia, 3
of 4 patients with acute polydipsic hyponatremia had seizures
[101. The mortality rate from acute symptomatic hyponatremia
is equally difficult to determine. Arieff quotes a mortality rate of
approximately 50% [5, 33]. On the other hand, none of the 10
acutely hyponatremic patients reported by Sterns had perma-
nent neurologic sequelae [10]. In fact, of 146 patients who
sustained seizure and/or coma from hyponatremia, only 3
patients died and 3 patients had neurologic sequelae [6]. How-
ever this review, which examined published series of patients
who developed seizures or coma from acute hyponatremia,
excluded all single case reports of fatalities or series devoted to
adverse outcomes, one of which reported 9 deaths [2]. Also,
other reports were overlooked in this review, including the one
by Burns and Spradlin [49] in which S fatalities were recorded in
subjects with psychogenic water intoxication, Finally, Sterns'
review included 37 infants with water intoxication, none of
whom died. Infants probably tolerate cerebral edema with
fewer untoward effects, and their outcome is not applicable to
individuals with non-expandable craniums. Thus, whereas a
50% mortality rate might be an exaggeration, estimates suggest-
ing that severe acute hyponatremia is a benign condition do not
do justice to this potentially catastrophic electrolyte distur-
bance.
Experience obtained in experimental animals also provides
divergent data as to the mortality rate of acute hyponatremia.
Most studies report that the induction of acute dilutional
hyponatremia is associated with high mortality rate, ranging
from 30% to 62% in the rabbit [21], rat [55, 56], and dog [57]. In
contrast, Sterns et a! report that despite the presence of
neurologic symptoms, none of 84 rats in which serum sodium
was lowered to approximately 100 mEq/liter within 26 hours
died [28]. The explanation for this marked discrepancy is not
readily apparent, but it might be related to the lower mortality
rate known to be associated with slower rates of induction of
hyponatremia [31].
In view of the adaptive changes, it is not surprising that
chronic hyponatremia is associated with much less striking
morbidity and mortality than is acute hyponatremia, In fact,
many patients with chronic hyponatremia are entirely asymp-
tomatic. The definition of chronicity is by necessity somewhat
arbitrary, but Sterns' suggestion of reserving this term for
disorders evolving over the course of more than 48 hours seems
reasonable [10]. In general, the symptoms of chronic hypona-
tremia are vague and nonspecific. Moreover, the severity of the
symptoms does not correlate well with the degree of hypona-
tremia. The symptoms include lethargy, disorientation, confu-
sion, gait disturbances, muscle cramps, and hiccups. With more
severe hyponatremia, the symptoms include tremor, stupor,
and coma; rarely, even seizures can occur [3, 10, 21, 58, 59]. No
neuropathologic studies exist in humans to explain these find-
ings, and experimental animals with symptomatic chronic hy-
ponatremia have neither cerebral swelling nor histologic
changes [3].
The mortality rate associated with chronic hyponatremia is
between 10% and 27% [60—63]. It is evident from all the
reported series, however, that the hyponatremia is simply an
indicator of an increased risk for death: the patients die of the
underlying disease that causes the hyponatremia rather than
from the electrolyte disturbance itself. Indeed, it is difficult to
document a single instance in which a patient died as a direct
consequence of chronic hyponatremia. Rather, such patients
appear to be at greater risk of sustaining a neurologic injury
consequent to treatment than to the electrolyte disturbance per
Se. An understanding of the cerebral events that accompany the
correction of hyponatremia may explain the pathogenesis of
such neurologic injury.
Consequences of treatment
In previously normonatremic animals, an acute increase in
extracellular fluid osmolality is associated with a loss of brain
water within 30 minutes that is quantitatively much lower than
would be predicted from ideal osmotic behavior, because water
loss is mitigated by the accumulation of sodium, chloride, and
potassium [64]. Most of the sodium and chloride entry into the
brain appears to be related to an increment in CSF flow into the
brain [25, 651, whereas potassium entry is consequent to
cellular uptake from plasma [65]. An analogous sequence of
events occurs during the treatment of hyponatremia. The in-
crease in plasma tonicity that accompanies correction of
chronic hyponatremia imposes on the brain, which already is
adapted to the hypoosmotic state, a need to promptly reverse
the adaptive process to prevent brain dehydration. The volume
regulatory process in this setting probably is not well main-
tained, perhaps because of preexisting cellular solute losses.
Verbalis et a! noted that after 5 days of hyponatremia, an
increment in plasma osmolality produced more cerebral dehy-
dration than did a comparable increment in control rats [30]. In
fact, as Figure 5 illustrates, the decrease in brain water content
per milliosmole change in plasma osmolality is much greater in
chronically hyponatremic rats (0.72 versus only 0.4 mlIlOO g dry
weight/mOsm in controls). The more recent study by Sterns et
al provides some insight into the mechanism and time depen-
dence of this response [28]. Rats that had been hyponatremic
for only 5 to 24 hours did not develop significant cerebral
dehydration when the hyponatremia was corrected. In contrast,
rats that had been hyponatremic for 72 hours developed cere-
bral dehydration whether the electrolyte alteration was cor-
rected spontaneously or with hypertonic saline. The mechanism
responsible for the cerebral dehydration appears to relate to a
slower recovery of brain potassium and even more strikingly to
a delayed reappearance of organic osmolytes [28, 32]. Although
brain content of most amino acids is initially restored during
treatment of hyponatremia in mice, the levels achieved remain
significantly below those of controls [32].
Pathology. Whereas the brains of animals who succumb to
untreated hyponatremia are frequently devoid of pathologic
lesions [21, 36, 57], extensive literature documents that correc-
tion of hyponatremia is associated with central pontine myelin-
olysis (CPM) or, more broadly, with demyelinating lesions in
the brain as a whole, the so-called "osmotic demyelination
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Fig. 5. The rate of water loss from the brain following abrupt increase
in serum sodium is lower in previously normonatremic rats (data from
Ref. 64) than in previously hyponatremic rats (data from Ref. 30).
syndrome" [6, 9]. In 1959 Adams eta! originally described CPM
in 4 malnourished and alcoholic patients [66]; the syndrome
subsequently was described in more detail by McCormick and
Danneel [67]. It represents a distinct pathologic entity charac-
terized by a symmetrical, midline, sharply delineated focus of
discoloration, and granulation reflecting demyelination in the
central basis pontis. The lesion is surrounded by normal tissue
with sparing of axonal fibers; reactive glial cell infiltration is
present, and numbers of oligodendrocytes are decreased. In
approximately 10% of patients, Wright et a! found extrapontine
lesions, for example, in the basal ganglia, internal capsule,
lateral geniculate body, or cortex [68]. Extrapontine lesions
appear to be more common in the syndrome associated with
hyponatremia. In Wright's study, all of the 12 patients with
extrapontine myelinolysis had electrolyte disturbances [68].
Also, isolated demyelination of the lateral geniculate ganglion in
association with CPM has been described in 6 patients [69].
Similarly, the 2 patients who had autopsies in Sterns' series [9]
also had extrapontine lesions, as did many in a series of patients
involved in a recent study using magnetic resonance [70].
Despite the almost universal presence of pontine lesions, the
term "osmotic cerebral demyelinating syndrome" probably is
more appropriate. I will discuss the pathogenesis of this syn-
drome shortly.
Clinical features. The clinical spectrum of pontine and ex-
trapontine myelinolysis is now recognized to be somewhat
broader than was originally thought. Symptoms can be absent
despite the presence of classic pathologic changes [71], and the
outcome is not uniformly fatal; the disease can improve and
even resolve [72, 73]. The salient clinical features of the disease
(recently summarized by Brennan and Ayus) [74] include: (1)
motor abnormalities that insidiously progress to flaccid quadri-
plegia, occasionally accompanied by respiratory paralysis; (2)
cranial nerve abnormalities manifesting as pseudobulbar palsy;
and (3) alterations in mental status including behavioral
changes [75], depression of sensorium, lethargy, and coma.
Seizures are uncommon. Clinical manifestations of the extra-
pontine lesions are rarely apparent because they are masked by
the dramatic picture produced by pontine involvement. The
symptoms referable to extrapontine lesions, when they do
occur, have been described by Dickoff and colleagues [76]. The
syndrome of pontine and extrapontine myelinolysis usually is
fatal in 3 to 5 weeks, but survival, frequently with residual
disability, is increasingly common.
Both CT scanning and magnetic resonance imaging have
greatly improved the premortem detection of this clinical entity
[70, 76—79]. The CT scan is not very sensitive to brain stem
abnormalities and can appear normal [70, 75, 80]. Magnetic
resonance imaging is superior because it permits visualization
of the brain stem and is sensitive to alterations in white matter.
However, as Patient 1 illustrates, the timing of the magnetic
resonance imaging is important, as it can be normal in the very
early stages, with lesions becoming apparent only one to two
weeks later [70, 811.
Because the pathologic lesions of CPM, their radiologic
evidence, or both are lacking in some patients who develop
brain damage after correction of hyponatremia, Arieff has
proposed that anoxic brain damage might be the cause of the
neurologic syndrome [2, 3]. Although this may well be the case
in the patients he described, particularly because many had
respiratory arrest, it must be emphasized that myelinolysis is
not a form of anoxic encephalopathy [82]. Although the clinical
sequence of initial improvement followed by worsening can
resemble anoxic encephalopathy, especially that associated
with carbon monoxide poisoning, the neurologic deterioration
due to myelinoysis starts earlier and progresses more rapidly
than that associated with hypoxia [82]. It seems more appropri-
ate, therefore, for us to consider these as two distinct clinical
and pathologic entities, either of which can be encountered
following correction of hyponatremia. One entity, delayed
hypoxic encephalopathy, may be a consequence of the seizures
(with consequent respiratory arrest and hypoxia) brought about
by a delay in the treatment of the disorder, and the other,
myelinolysis, may be a consequence of the treatment itself.
Patho genesis of the cerebral demyelination syndrome
Three years after originally describing CPM, Adams again
reported it in 2 patients with hyponatremia [83]. Conger et al,
however, were the first to call attention to the possible impor-
tance of the relationship to a hypotonic state [84]. Since then,
other groups have attested to the occurrence of hyponatremia in
patients with CPM [85—87]. In fact, in one review of CPM,
hyponatremia (serum sodium less than 130 mEq/liter) was
found in 61% of the cases [85]. In a large autopsy series,
however, a serum sodium less than 130 mEq/liter was noted in
only 25% of cases [87]. Also, of 110 patients who had CPM at
autopsy (not all of whom had measurements of electrolytes),
only 20% had a serum sodium of less than 125 mEq/liter [88]. In
fact, hypernatremia also has been noted [25, 86, 87, 89].
Furthermore, as I noted earlier, neither in humans nor in
experimental animals is hyponatremic encephalopathy associ-
ated wtih a specific pathologic picture, except of course for
cerebral edema in the acute phase [11, 21, 52, 57, 82]. Specifi-
cally, severe prolonged hyponatremia is not associated with
myelinolysis [55, 741. On this basis one can say unequivocally
that hyponatremia per se is not the underlying cause of CPM,
nor is hyponatremia necessary for its development.
If hyponatremia per se is not the proximate cause of the
demyelinating process, could correction of the disorder be
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responsible for the clinical and pathologic picture? This possi-
bility gains credence from the observation that neurologic
deterioration frequently follows the clinical improvement occa-
sioned by restoration of the serum sodium concentration, as in
the first patient presented today. Several early case reports
suggest that a rapid increase in serum sodium could be impli-
cated in the pathogenesis of CPM [83, 90, 91]. Norenberg et a!
focused attention on this possibility by describing 12 hypona-
tremic patients with CPM whose serum sodium was raised by
20—30 mEq/Iiter over a 2- to 4-day period [8]. Symmetrical
demyelinative lesions in various areas of the central nervous
system also were produced in rats given hypertonic saline on
day 4 of experimental hyponatremia [7, 92]. Similar lesions
have been demonstrated in other experimental animals that
survived the acute hyponatremic insult and in which the hy-
ponatremia was rapidly corrected; such studies have been done
in the dog [57], rat [55], and rabbit [93].
The interval at which the correction occurs is important.
Thus, rabbits [93] or rats [28, 94] treated after 3 to 4 days of
hyponatremia develop cerebral lesions, whereas those in which
the hyponatremia is corrected within 24 hours do not. These
observations, as well as numerous reports in humans [8—10,
95—97], provide compelling evidence supporting the view that
correction of hyponatremia of greater than 24-hour duration
plays a central role in the development of cerebral demyelina-
tive lesions and the accompanying clinical picture. Two impor-
tant questions with therapeutic implications have not yet been
addressed adequately, however. Is the rate of correction im-
portant? And, is the magnitude of correction the critical deter-
minant of outcome? I would like now to turn to a consideration
of these questions.
These two variables in the correction of hyponatremia are not
readily dissociated because a rapid correction rate usually is
accompanied by a greater absolute magnitude of correction
over a given time period. Nonetheless, this distinction is
potentially of great importance in the approach to the patient
with symptomatic hyponatremia. Although most of the early
descriptions of CPM focused on the rate of correction as the
critical factor, this issue remains controversial. On the other
hand, since Heiwig first described the revival of a moribund,
water-intoxicated patient following infusion of 130 ml of 5%
sodium chloride [98], many authors have documented that
serum sodium can be increased rapidly without producing any
deleterious neurologic consequences [21, 99—101]. Specifically,
in Ayus' series, all 7 patients whose serum sodium increased
from 100 to 128 mEq/liter at an average rate of 2.4 mM/liter/hr
remained free of neurologic symptoms [99]. Likewise, in his
subsequent experience, none of the 30 patients whose serum
sodium increased at an average rate of 1.3 mEq/liter/hr over 17
hours had evidence of demyelinating lesions or clinical neuro-
logic damage [4]. Others have made similar observations [101].
Of 5 hyponatremic patients with seizures who were given 29.2%
sodium chloride, the 4 who were promptly treated had favor-
able clinical outcomes [100]. Also, in subjects with psychogenic
polydipsia, the treatment of 14 episodes of symptomatic hy-
ponatremia at a rate of 1.4 mEq/liter/hr was not associated with
any neurologic sequelae [54]. In fact, in a retrospective analysis
of the literature, Ayus and colleagues found that the mortality
rate of symptomatic hyponatremia was 42% in patients treated
"slowly" (less than 0.7 mM/liter/br) as compared with 7% in
patients treated at a rate of 2 mM/liter/hr [1]. The exclusion of
the high-risk alcoholic patients somewhat biases this analysis
that supported a rapid correction rate of the hyponatremia.
These observations contrast with the experience of Sterns [10],
who found that neurologic complications occur more commonly
in patients whose hyponatremia was corrected rapidly. This
finding, however, applied only to patients with chronic hypona-
tremia; 10 acutely hyponatremic patients did well with correc-
tion rates as high as 1.9 to 2.4 mM/liter/hr. Furthermore, a close
analysis of Sterns' report reveals that the 7 patients with
chronic hyponatremia who developed neurologic sequelae ex-
perienced a wide range of correction, with hyponatremia in 3
patients having been corrected at a rate less than 0.7 mM!
liter/hr. Other investigators have reported similar experiences
[102]. Such observations have prompted the suggestion that the
absolute magnitude, rather than the rate of correction, is the
critical determinant of outcome [4]. Thus, in a combined
prospective and retrospective analysis of patients with demy-
elinating lesions, Ayus and coworkers concluded that an incre-
ment in serum sodium of more than 25 mEq/liter in the initial 48
hours, and not a specific rate of correction, is the primary risk
factor for the production of the cerebral lesions [4].
Do experiments performed in animals shed light on this
controversy? Analysis of such studies reveals a number of
points of agreement. Even rapid correction of hyponatremia of
short duration is associated with few [94] or no neurologic
abnormalities [28]. Likewise, rapid correction of sustained
hyponatremia is associated with a high incidence of myelinosis
and neurologic impairment in the dog [57], rabbit [93], and rat
[7, 28, 551. Whereas these studies clearly demonstrate that
demyelination can occur without overcorrection of the serum
sodium, they are characterized by both a high rate and large
magnitude of correction. The possibility that the latter variable
is important was suggested by Laureno, who observed that
dogs in which the serum sodium rose by less than 15 mEq/liter
in one day and less than 20 mEq/liter in 2 days developed no
lesions, whereas those in which these parameters were ex-
ceeded had a high incidence of lesions (approximately 80%)
[57]. A similar suggestion emerged from the studies of Ayus et
al [55]. This group noted a lower incidence of lesions in rats in
which hyponatremia was rapidly corrected but only to mildly
hyponatremic levels (130 mEq/liter) rather than to normo- or
hypernatremic levels. This issue has been studied further by
these investigators and reported on recently [56]. As Table 1
shows, the spontaneous correction of mild hyponatremia by an
increment in serum sodium of 16 9 mEq/liter and, even more
strikingly, the rapid correction of severe hyponatremia by 19
3 mEq/liter over the first 24 hours was associated with low
(15%) and no mortality, respectively, and with no development
of brain lesions in either case. In contrast, and in accordance
with previous observations, an increment in serum sodium over
24 hours of 25 1 mM achieved spontaneously or of 34 10
mM in response to hypertonic saline infusion was associated
with a high mortality rate (68%—88%). These experiments
represent the counterpart to the human experience that I
described [4] and support the view that correction by less than
25 mEqfliter in the first 24 hours correlates best with survival.
Employing an elegant model of chronic, seemingly asympto-
matic hyponatremia in the rat, Verbalis and Martinez recently
showed that demyelination might be a function of both the rate
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Table 1. Serum sodium profiles of rats with hyponatremiaa
Serum sodium (mEqIL)
Group Day 4 Day 5 Mortality
1. Spontaneous correction of 124 4" 141 7 16 9 15% None
mild hyponatremia (120.-l35) (129—152) (3—32)
2. Spontaneous correction of 107 8C 133 16 25 11 68% Myelinolysis
symptomatic hyponatremia (89—117) (104—156) (6—43) in 2 of 8
3. Rapid correction of 107 5C 126 5 19 3 0% None
symptomatic hyponatremia (100—119) (118—134) (14—24)
serum sodium <25 mEq/L
4. Rapid correction of 102 6C 136 12 34 88% Cellular
symptomatic hyponatremia
serum sodium >25 mEq/L (93—112) (119—158) (25—49)
necrosis
a All values are expressed as mean 5D. The numbers in parentheses represent range. Initial serum sodium was 145 in all groups. (From Ref.
56.)bP < 0.0001 versus Groups 2—4.
P NS between Groups 2—4.
d P < 0.001 versus Group 3.
and magnitude of correction [103]. Demyelination was not
observed in any rat in which the maximal correction rate was
less than 2.5 mEq/Iiter/hr and the magnitude of the increase in
serum sodium was less than 25 mEq/liter. If either of these
limits was exceeded, the demyelination rate was 60%.
Because the rate and magnitude of correction are not entirely
independent of each other, these studies suggest that one
should pay attention to each of these variables when designing
therapy for the symptomatically hyponatremic patient. In this
regard, note that both of these limits were exceeded in the
course of correcting the hyponatremia in the first patient
presented.
Factors predisposing to the development of neurologic dis-
ease. Females appear to be more likely than males to develop
neurologic damage associated with hyponatremia [3, 5]. In fact,
all the patients in Arieff' s report who had postoperative hypona-
tremia, respiratory arrest, and permanent neurologic damage
from the hypoxic insult were female [21. In surveying the
literature, Arieff found that 88% of 75 patients with postopera-
tive hyponatremia were female [5]. Furthermore, with only one
exception, all males recovered fully, but more than 50% of the
females either died or had residual neurologic damage [5]. This
gender difference in susceptibility also was noted in a more
recent communication [104]. Of 10 males with severe hypona-
tremia (serum sodium, 102 mEq/liter) that was corrected rap-
idly, none had neurologic sequelae, even though 4 of them had
seizures. In contrast, all of the 34 females with a serum sodium
of 115 2 mEq/liter who were treated slowly or not at all had
respiratory arrest and seizures, and all either died or had brain
damage. Studies in rabbits suggest that cerebral adaptation to
hyponatremia might be more efficient in males than in females
[104], thereby resulting in less cerebral edema. The loss of
cellular potassium is important in this process, and such loss
occurs not only in cerebral cells but also in Ehrlich cells [105]
and lymphocytes [106] exposed to a hypotonic environment. A
decrement in potassium efflux, perhaps mediated by an effect of
progesterone to inhibit sodiumlpotassium-ATPase [107], could
culminate in such a process. Alternatively, other mechanisms
such as a decrease in CSF flow or an alteration in vascular
permeabilty might be operative.
Although the observation by Ayus and Arieff clearly points to
a female predisposition to neurologic injury in postoperative
hyponatremia, this preponderance might not be as striking in
other clinical settings. Of 10 patients who died of polydipsic
hyponatremia, 3 were males [49]. It is also of note that despite
many reports of acute hyponatremia in women given oxytocin
[41, 42, 46], neurologic sequelae are remarkably absent. In fact,
in a survey by Daggett et at, of 10 patients who sustained
hyponatremic seizures, the 4 survivors all were young women
who had received oxytocin [1081.
A survey of the gender distribution among patients with
hyponatremia-associated myelinolysis reveals only a slight fe-
male preponderance. Of the 12 patients originally described by
Norenberg, one-half were female; a similar distribution also
was observed among the 12 patients reported by Ayus et al [4].
Females predominate in Sterns' series [9] and in a literature
survey that includes Sterns' data [4]. Most of the patients
described by Sterns as having myelinolysis or delayed neuro-
logic deterioration were elderly women who had taken thiazide
diuretics [9, 10]. The susceptibility of this subgroup of patients
to the neurologic consequences of hyponatremia is beyond
doubt. It is by no means clear, however, that the process is
limited to myelinosis. Thus, Ashoun reported 8 such women
who were hospitalized with severe neurologic symptoms and
who, with one exception, recovered when the hyponatremia
was corrected at a rate of 0.78 mM/liter/hr [109]. These patients
had neither the clinical nor the radiologic manifestations of
CPM. A less favorable outcome was described by Ashraf et al
in 7 elderly patients, 5 of whom were women; all 5 either died
or had neurologic residua, whereas the 2 men recovered [110].
Although no pathologic correlates were obtained, the clinical
course did not suggest CPM, and CT scans did not reveal
demyelinating lesions.
In summary, the available evidence taken together points to
a predominantly female susceptibility to postoperative hypona-
tremia and, in the elderly, to thiazide-associated hyponatremia.
Both sexes appear to be at equal risk for developing demyeli-
nating neurologic disorders.
Although gender does not appear to be a risk factor for the
development of demyelinating lesions, such lesions clearly
Absolute change
in first 24 hrs of
correction
Brain
lesions in
survivors
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occur with greater frequency in individuals with certain preex-
isting abnormalities. Of these, alcoholism and malnutrition are
the most frequently. The mortality rate from hyponatremia in
alcoholics is significantly increased [1]. Likewise, a significant
proportion of patients described with CPM are malnourished
alcoholics, and such patients frequently have not had severe
hyponatremia. Therefore, patients with an underlying meta-
bolic disorder or preexisting CNS disease appear to be partic-
ularly susceptible to osmotic injury. In this regard, cerebral
lesions are difficult to produce in previously normonatremic rats
by acutely increasing serum sodium to hypernatremic levels.
Although this difficulty might be related to the greater ability of
the normal brain to protect against dehydration (Fig. 4) or to the
absolute increment in serum sodium being smaller, cerebral
lesions can be produced if a previous metabolic insult (such as
hypoxia) precedes the elevation of serum sodium (Ayus JC,
personal communication).
Potassium depletion is a metabolic abnormality frequently
encountered in groups at high risk of developing CPM. As was
the case in the first patient presented today, profound hypokale-
mia frequently accompanies the hyponatremia in many, albeit
not all, reported cases. The extent to which the brain partici-
pates in the adaptation to potassium depletion has not been
established. Because this cation is important in the cerebral
response to hyponatremia, it is possible that potassium deple-
tion alters this response. However, even if the adaptive re-
sponse is intact, the restoration of cell solutes that protect
against dehydration in the correction phase depends on the
return of potassium from the systemic circulation, This process
might be limited in potassium depletion and possibly causes
more cerebral dehydration and osmotic injury. Although these
possibilities require experimental verification, only a minority
of patients with CPM established pathologically were in fact
severely hypokalemic [87]; moreover, chronically hypona-
tremic rats in which lesions were demonstrated did not have
overt potassium depletion (Verbalis J, personal communica-
tion). Nonetheless, the clinical observation is striking and
worthy of further investigation.
A prudent approach
A consensus regarding the optimal therapeutic approach to
the hyponatremic patient has not yet fully emerged [2, 9, 111,
112]. It is evident that not every hyponatremic patient should be
treated in a standard manner. I believe that recognition of and
adherence to a few principles can guide the clinician away from
the simplistic dilemma between a "too-fast-too-soon" versus a
"too-slow-too-late" approach. A given approach can be haz-
ardous in one setting yet be the most appropriate action in
another. The clinician must recognize the following: (1) The
neurologic consequences of hyponatremia are both clinically
and pathologically heterogeneous. In susceptible individuals,
these consequences can arise from either the failure to treat
promptly or from overly aggressive treatment of the disorder.
(2) The presence or absence of symptoms is an important
determinant of when to intervene therapeutically and when to
withhold treatment. (3) The acuteness or chronicity of the
disturbance has a marked effect on the urgency with which
treatment should be undertaken. The old adage should be
heeded strongly in this instance: diseases that develop quickly
require prompt correction; those that develop slowly should be
corrected at a proportionately slower pace.
Even in the midst of the prevailing controversy, there are
several issues of general agreement. Few would argue that the
essentially asymptomatic patient is best managed conserva-
tively by water restriction, even when the serum sodium is
extremely low. Although when carefully tested, most of these
patients do display subtle neurologic dysfunction, the hypona-
tremia is most likely to be chronic, so one should resist the
temptation to correct the electrolyte disorder rapidly. In fact,
even with a conservative approach, the rate of increase in
serum sodium should be closely monitored because the coinci-
dent reestablishment of normal diluting ability, when coupled
with water restriction, can culminate in a correction rate higher
than intended. Likewise, a consensus seems to be emerging
regarding therapy of the patient with acute symptomatic hy-
ponatremia. In this setting, the risks of cerebral edema, sei-
zures, and possible respiratory arrest clearly outweigh the risk
of overly rapid correction. The symptoms usually respond
promptly when the hyponatremia is corrected, and the reduc-
tion in cerebral swelling may prevent a lethal outcome. This can
be achieved by the administration of furosemide in conjunction
with 3% sodium chloride, as we have described in detail [113].
One should recognize, however, that it is frequently difficult to
ascertain precisely whether the electrolyte derangement is
indeed acute.
Most patients with acute symptomatic hyponatremia are
either hospitalized women with postoperative hyponatremia,
patients with water intoxication due to psychogenic polydipsia,
or elderly females for whom thiazide diuretics have recently
been prescribed. The great majority of patients who come to the
physician's attention have hyponatremia of unknown duration
that is most likely subacute, if not chronic. Such patients, when
symptomatic, present the most difficult therapeutic dilemma
because the balance of risk and benefit is difficult to ascertain.
On the one hand, the presence of neurologic symptoms is
evidence of ongoing dysfunction. Although the pathologic cor-
relates of this syndrome are sparse, symptoms are most likely a
consequence of the accompanying cerebral edema. On the
other hand, these patients—particularly the subgroup with
alcoholism, malnutrition, or liver disease—are prone to develop
the demyelinating syndrome when hyponatremia is corrected. I
think a prudent balance between the risks and benefits of
treating these patients entails a prompt increment of the serum
sodium by approximately 10%. In chronic hyponatremia the
increment in brain water content is modest and rarely exceeds
10%, so an increase in serum sodium by 10 to 12 mEq/liter
should reverse any remaining cerebral edema. Thereafter a
slower correction rate that can be achieved simply by restrict-
ing the patient's water intake should suffice. At no time in the
process should the rate of correction be allowed to exceed 2.5
mEq/liter/hr. Furthermore, the increment in serum sodium
should not be allowed to exceed 20 mEq/liter/day. Note that
these guidelines do not set any particular optimal level of serum
sodium. A goal of 125 to 130 mEq/liter may be excessive for a
patient such as the first one discussed today, in whom the initial
serum sodium was lower than 100 mEq/liter.
One of the major difficulties in managing hyponatremia is
precisely controlling the rate at which the serum sodium is
increased. Although a calculation of the excess in body water is
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readily available, the rate at which serum sodium will rise is a
function not only of the rate at which hypertonic saline is given,
but also the rate at which free water is excreted. If a patient is
excreting a dilute urine, the increment in serum sodium can
exceed that calculated from the rate of hypertonic saline
infusion. The first patient presented today was excreting free
water, and her serum sodium was increasing spontaneously
prior to the infusion of hypertonic saline; the infusion markedly
accelerated the correction rate and culminated in both a rate
and magnitude of correction that clearly placed the patient at
risk of developing the demyelinating disease to which she
eventually succumbed. Now cognizant of the chronic nature of
the patient's electrolyte disturbance, we know that a more
conservative approach would have been more prudent. In
contrast, prompt recognition and treatment of the hyponatremia
in Patient 2 might have prevented her seizure, respiratory
arrest, and eventual death.
I believe that we can largely avoid the untoward events in the
management of hyponatremia, such as those in these two
patients, if we adopt a thoughtful, balanced approach that takes
into account the presence or absence of significant symptoms,
the chronicity of the process, and the susceptibility of certain
patients to the complications of treatment as well as of no
treatment. Coupling this approach with careful patient obser-
vation and with frequent monitoring of urinary sodium and
water excretion as well as serum sodium concentration offers a
rational basis for individualizing therapy.
Questions and answers
DR. GEORGE KALOYANIDES (Division of Nephrology, State
University of New York at Stony Brook, Stony Brook, New
York): In the first case you presented, a significant delay
occurred before the patient manifested the signs and symptoms
of pontine myelinolysis; at least 12 hours elapsed between the
time the serum sodium was corrected to 131 mEq/liter and her
manifestations of neurologic deficit. First, how common is such
a delay in the syndrome? Second, what does such a delay teach
us about the pathogenesis of the disorder? By the time the
sodium was raised to 131 mEq/liter, cellular dehydration al-
ready would have occurred, yet the clinical expression of the
pathologic process was delayed. Finally, why the predilection
for the pons?
DR. BERL: The delay manifested by the first patient, who had
an asymptomatic period following correction of hyponatremia,
is commonly observed. In fact, it is this delay that has prompted
the suggestion that some patients have posthypoxic encepha-
lopathy rather than CPM, because such a delay is reminiscent
of that seen with hypoxic encephalopathy, particularly with
carbon monoxide poisoning. However, as recently emphasized
by Laureno and Karp [82], the clinical and pathologic features
of these two entities are different and should not be confused.
In regard to your question as to why the predilection for the
pons, two theories have been proposed. The so-called "grid"
theory proposes that the neurons, oligodendrocytes, and my-
elinated fibers in the pons are tightly and closely arranged and
that the myelinated fibers are "strangulated" by edema of the
cellular structures. The "osmotic-endothelial-injury" theory
maintains that the areas of injury have a typical gray/white
matter mix. Gray matter is approximately five times more
vascular than white matter. The rapid osmotic changes in the
endothelial cells in the gray matter is thought to release "my-
elotoxic factors" that could cause local demyelination.
DR. NAND K. WADWA (Department of Medicine, SUNY at
Stony Brook): You mentioned that intracellular depletion of
potassium and amino acids occurs in the brain. Would admin-
istration of potassium and/or amino acids be helpful in prevent-
ing myelinolysis? What happens to plasma amino acid levels in
hyponatremia?
DR. BERL: I don't know of any studies that have measured
plasma amino acids in hyponatremia, nor am I aware of
experiments that have systematically assessed the effect of
readministering potassium and amino acids. Such studies
clearly need to be done. As a matter of practical management,
potassium is, in fact, frequently given to hypokalemic patients,
as was the case with the first patient presented. What role
potassium plays in the pathogenesis of the demyelinating pro-
cess needs to be assessed.
DR. JORDAN J. COHEN (Dean of Medicine, SUNY at Stony
Brook): Central pontine myelinolysis has been described in
circumstances other than hyponatremia. What are those cir-
cumstances and what, if anything, do they have in common
with hyponatremia?
DR. BERL: You are correct. In the larger series of patients
with CPM, only a minority (approximately 20% to 30%) have
hyponatremia. In one of the larger series of 37 patients [87],
43% had a malignant neoplasm, 27% had a variety of chronic
pulmonary disorders, and 14% had renal failure. We also are
seeing an increasing number of reports from burn units. An
association with alcohol abuse and malnutrition is frequently
mentioned.
DR. MARTIN LIEBOWITZ (Associate Chairman, Department
of Medicine, SUNY at Stony Brook): Does it matter how a
patient becomes hyponatremic? At the same serum sodium
level, do patients with secondary water retention following salt
and water depletion have the same risks and consequences
during the replenishment period as do patients with primary
water retention?
DR. BuRL: The problem has never been looked at from that
perspective. The vast majority of the reported patients appear
to have had euvolemic rather than hypovolemic hyponatremia,
although those patients with thiazide-associated hyponatremia
may be somewhat hypovolemic. Likewise, all the animal mod-
els involve primary water retention. It is not clear, therefore,
whether the underlying pathogenesis of the hyponatremia alters
the risk for neurologic complications.
DR. COHEN: Your recommendation for treatment appears to
be in keeping with the classic teaching that asymptomatic
patients should not be treated aggressively no matter how
hyponatremic they are. Are there any instances in which
patients treated with water restriction alone—with the rela-
tively slow correction that such restriction produces—have
developed pontine myelinolysis?
DR. BERL: As you state the question, the answer is probably
no. However, nyelinolysis has been reported with "spontane-
ous" correction of hyponatremia both in humans and in exper-
imental animals under circumstances in which large volumes of
dilute urine are excreted. If diluting ability is reestablished
while hyponatremia is still present, water excretion can in-
crease markedly, thereby resulting in rapid correction of hy-
ponatremia, particularly if water restriction is also being im-
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posed. Therefore, one needs to monitor serum sodium in these
patients to avoid excessively rapid correction; if necessary,
some water intake should be allowed.
DR. RICHARD BARNETT (Department of Nephrology, SUNY
at Stony Brook): The first patient today had a very low BUN, a
low creatinine, and a low uric acid level; all of these suggest
volume expansion. Yet the patient was not treated with a loop
diuretic. How critical do you think it is to administer diuretics
along with hypertonic saline in the management of such pa-
tients?
DR. BERL: I do believe that loop diuretics are important in the
management of acute, symptomatic hyponatremia. Because
these patients are in a state of marked water excess, the goal of
therapy is to bring about the excretion of free water. By their
action on both the thick ascending limb and the collecting duct,
loop diuretics also impair free-water reabsorption, thereby
increasing water excretion. Furthermore, the diuretics promote
the excretion of the sodium chloride infused in the hypertonic
saline and thereby prevent sodium overload, which is, of
course, particularly undesirable in patients with cardiac dis-
ease.
Da. COHEN: You reminded us earlier that water restriction
alone, albeit rarely, can be associated with pontine myelinolysis
if the ensuing water diuresis is brisk. This observation prompts
a speculative question. In the vast majority of patients with
hyponatremia of any substantial duration, excess antidiuretic
hormone is present in the circulation. Indeed, the search has
been on for some time to find an effective antagonist to ADH
because such an antagonist should provide a more specific way
to treat chronic hyponatremia. Now one wonders whether such
an agent would in fact be useful. Might it produce a water
diuresis that is too rapid?
Da. BuRL: You raise a concern that actually has been tested
in experimental animals. Dr. Joseph Verbalis reported at the
1989 AFCR meetings on the treatment of chronically hypona-
tremic rats with these antagonists. The serum sodium rose by 23
mEq/liter and the maximal change was 4.5 mEq/liter/hr. Mor-
tality was high (approximately 85%), and 55% of animals had
demyelination. Thus, if and when vasopressin antagonists be-
come available, this potential complication will need to be
considered.
DR. COHEN: You noted that the protection of brain volume in
acute hyponatremia is almost entirely due to a reduction in
extracellular fluid volume. This reduction appears to occur in
the very early stages of water intoxication. If brain extracellular
fluid volume accounts for only 20% of brain water, as is the case
elsewhere in the body, this mechanism would have obvious
limitations as a defense against brain swelling. Do you agree?
DR. BERL: You are correct in stating that a decrement in
extracellular water has a limited effect as a defense against brain
swelling. Nonetheless, the fact that it does not increase with
acute hyponatremia and, in fact, decreases somewhat (from
approximately 90 to 75 mL/100 g dry weight) [231 does mitigate
against the swelling. Thus, while brain water would be expected
to increase by appoximately 65 mlIlOO g dry weight (50 from the
intracellular and 15 from the extracellular space), brain water
only rose by 35 mlIlOO g dry weight because the 50 ml gain in the
intracellular space was accompanied by the 15 ml/lOO g dry
weight loss from the extracellular space.
Da. COHEN: You also noted that young children with acute
hyponatremia might be at lower risk for neurologic sequelae
because flexible suture lines in the skull permit brain volume to
expand. Is this mechanism of protection well documented?
DR. BERL: This is quite well documented in newborn puppies
[27], in which the decrement in ECF volume does not occur and
swelling is more marked. Observations on actual neurologic
sequelae are not available. However, the review by Sterns [61,
in which none of the 37 patients with infantile water intoxication
had either brain death or neurologic sequelae, is compelling.
DR. COHEN: Italso could suggest that the critical factor in the
pathogenesis of those acute symptoms is pressure per se and
not cell volume or hypotonicity.
DR. BERL: The cell volume changes are most certainly not
specific to the brain. It is the limitations placed by the cranium
that cause the increments in pressure and, presumably, the
symptoms.
DR. MARK GRABER (Chief of Nephrology, VA Medical Cen-
ter, Northport, New York): The cellular response to hyperto-
nicity and hypotonicity has been studied extensively using cells
in tissue culture. Do such experimental model systems shed any
light on the clinical problem?
DR. BuRL: The control and regulation of cell volume, as you
state, is of enormous interest and has been subject to much
investigation. Both the renal medulla in its naturally hypertonic
environment, as well as the brain in the setting of hyperna-
tremia, have been shown to generate cellular solutes (os-
molytes), such as myoinositol, glycerophosphocholine (GPC)
and betaine. to prevent cellular dehydration. The emphasis in
the discussion today was on the adaptation to hypotonicity and
loss of cellular solutes. Whether a failure to generate osmolytes
normally is responsible for the more profound cellular dehydra-
tion that occurs when tonicity is increased in brains previously
adapted to hypotonicity is not known (Fig. 4). This is possible,
but it must be kept in mind that even the restoration of lost
solutes (for example, potassium, amino acids) is delayed.
DR. LIEBOWITZ: By what mechanism do you think the first
patient presented today became hyponatremic? Is it possible
that the neurologic lesion came first and water retention fol-
lowed?
DR. BERL: Many central nervous system processes cause the
secretion of antidiuretic hormone which, if accompanied by
excessive water intake, can culminate in hyponatremia. I doubt
that in this patient a neurologic lesion preceded the hypona-
tremia. When the hyponatremia was corrected, she was neuro-
logically intact, the CT scan was normal, and the first MRI did
not support the presence of a CNS lesion. In this woman with
chronic anxiety, psychogenic water drinking might have en-
sued, and the thiazide diuretics might have limited her ability to
excrete water.
DR. CHRISTOS CARVOUNIS (Chief of Nephrology, Nassau
County Medical Center, New York): The first patient had severe
potassium depletion, judging from her serum potassium of 1.6
mEq/liter. Given that severe potassium depletion has many
adverse effects on renal function and cell metabolism, what
role, if any, do you think this deficit had in the pathogenesis of
the hyponatremia? In addition, in this patient substantial kali-
uresis was present, and one might anticipate that administration
of sodium chloride with or without diuretics might aggravate the
potassium losses by accelerating distal delivery and exchange.
Shouldn't she have been treated aggressively with potassium?
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Indeed, some hyponatremic patients appear to respond to
potassium administration alone.
DR. BERL: Potassium depletion can cause hyponatremia
without accompanying volume contraction. Fishman and col-
laborators described such patients a few years ago. The mech-
anism is not fully understood. I do agree with you that potas-
sium repletion should be undertaken promptly and
aggressively. It is also likely that many of the same patients are
also magnesium deficient, although this has been measured less
frequently. I do want to reiterate, however, that only a small
minority of patients with CPM (approximately 10%) are hypo-
kalemic. I suspect that a much higher percentage of hypona.-
tremic patients who develop CPM are also potassium depleted.
DR. MICHAEL GOLIGORSKY (Department of Medicine, SUNY
at Stony Brook): Some fish can adapt when they go from sea
water to fresh water. Do you know of any studies of brain
metabolism in this setting? I'm especially intrigued because
taurine appears to be an important osmolyte in fish brain as well
as in mammalian brain.
DR. BERL: This is a interesing possibility. I am unaware of
studies on brain metabolism in the transition from sea to fresh
water. We have learned a lot about osmoregulation from fish,
and this may well be another fruitful area of investigation.
DR. ZELIK FRISCHER (Department of Urology, SUNY at
Stony Brook): Hyponatremia occurs with some frequency fol-
lowing transurethral resection of the prostate, yet neurologic
sequelae do not appear to be common in this setting. Is this
impression correct and, if so, why is this the case?
DR. BERL: Your impression is indeed correct and has been
used to support the important gender difference in regard to
long-term sequelae of hyponatremia. A recent abstract reported
10 males who underwent prostatectomy and became very
hyponatremic (mean serum sodium 102 mEq/liter) [831. Al-
though 4 of these patients had seizures, none had long-term
sequelae. This contrasts with the very poor outlook in women
who develop acute hyponatremia, particularly if accompanied
by a respiratory arrest. This group has an inordinately high
mortality rate.
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